NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be participating at the following upcoming investor conferences:
- Baird 2019 Global Healthcare Conference in New York, NY at 3:10 p.m. ET on Wednesday, September 4, 2019
- Citi 14th Annual Biotech Conference in Boston, MA at 12:45 p.m. ET on Thursday, September 5, 2019
Webcast information for these events will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept’s website for approximately two weeks.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
For more information about Intercept, please contact:
Media inquiries: email@example.com